Insider Buying: Indivior (NASDAQ:INDV) CAO Acquires $53,535.00 in Stock

Indivior PLC (NASDAQ:INDV) CAO Woodrow Anderson bought 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were purchased at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the transaction, the chief accounting officer owned 27,638 shares of the company’s stock, valued at $986,400.22. The trade was a 5.74% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Indivior Stock Performance

Shares of INDV opened at $34.87 on Friday. Indivior PLC has a fifty-two week low of $22.22 and a fifty-two week high of $42.81. The stock has a fifty day moving average of $39.33 and a two-hundred day moving average of $36.00. The company has a market capitalization of $4.12 billion, a PE ratio of 12.50 and a beta of 0.86.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The business had revenue of $343.00 million during the quarter. As a group, equities research analysts forecast that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after buying an additional 1,299,425 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Indivior by 101.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock valued at $228,611,000 after acquiring an additional 3,201,639 shares in the last quarter. Vanguard Group Inc. boosted its position in Indivior by 57.9% during the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after purchasing an additional 2,008,078 shares during the period. California State Teachers Retirement System purchased a new stake in Indivior during the 2nd quarter worth $201,163,000. Finally, State Street Corp increased its holdings in Indivior by 65.5% in the 4th quarter. State Street Corp now owns 4,659,281 shares of the company’s stock valued at $167,175,000 after purchasing an additional 1,844,532 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on INDV. Barclays cut their price objective on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Craig Hallum reiterated a “buy” rating and issued a $53.00 price target on shares of Indivior in a report on Tuesday, August 4th. Finally, Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Indivior presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.17.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.